| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 8 securities · may seek to influence control | ||||||
|
Aterian, Inc.
13D/A
ATER · 02156U200
|
3.1% |
9/29/2026
Event 9/25/2026
|
||||
|
Quantum Cyber N.V.
13D/A
QUCY · N5436L119
|
94.3% |
8/7/2026
Event 8/5/2026
|
||||
|
KALA BIO, Inc.
13D/A
KALA · 483119301
|
3.9% |
7/2/2026
Event 5/20/2026
|
||||
|
Indaptus Therapeutics, Inc.
13D/A
INDP · 45339J105
|
47.9% |
3/24/2026
Event 3/23/2026
|
||||
|
KALA BIO, Inc.
13D
KALA · 483119202
|
5.2% |
2/6/2026
Event 1/30/2026
|
||||
|
NovaBay Pharmaceuticals, Inc.
13D/A
NBY · 66987P409
|
4.99% |
1/29/2026
Event 10/21/2025
|
||||
|
Cyclacel Pharmaceuticals, Inc.
13D/A
CYCC · 23254L801
|
0% |
8/8/2025
Event 8/5/2025
|
||||
|
FiEE, Inc.
13D/A
MINM · 60365W102
|
35.1% |
3/10/2025
Event 2/18/2025
|
||||
| Schedule 13G · 2 securities · passive | ||||||
|
Universal Safety Products, Inc.
13G/A
UUU · 913821302
|
9.9% |
5/7/2026
Event 1/27/2026
|
||||
|
Matinas BioPharma Holdings, Inc.
13G
MTNB · 576810303
|
9.8% |
8/19/2025
Event 8/15/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.